SGK1 and Hydrocephalus: The current studies highlight a novel drug target, serum- and glucocorticoid-induced kinase 1 (SGK1) within the TRPV4 pathway and show the efficacy of an inhibitor of SGK1 in the treatment of hydrocephalus in vivo and mechanistically in a human cell line in vitro.